ductal carcinoma in situ

Researchers traced clonal populations with shared copy number profiles back to their location in tissue samples, confirming patterns that may have clinical relevance.

With more evidence for clinical utility in the scientific literature, the company expects finalized Medicare coverage before the end of the year.

The firm's revenues were hit by currency translation and differences in the timing of test reimbursement compared with the previous year's quarter.

In a large DCIS cohort, researchers showed the ability of Oncotype DX score to assess recurrence risk in patients treated with breast conservation surgery.

NEW YORK (GenomeWeb) ─ Genomic Health reported after the close of the market Tuesday that its third quarter revenues were up five percent year over year, falling slightly short of the Wall Street consensus estimate.

This article has been corrected to note that Brad Cole is Genomic Health's CFO and COO.

NEW YORK (GenomeWeb News) – Saying that Genomic Health's growth could fall short of consensus expectations, financial services firm Raymond James today downgraded shares of the Redwood City, Calif.-based firm's stock to Underperform from Market Perform.

NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market on Friday that the national Medicare contractor for the firm's Oncotype DX breast cancer test has expanded Medicare coverage for the test.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.